Summit Reports 25% Lower Death Risk in Biliary Tract Cancer Trial

Your call?🐂 Bullish🐻 Bearish

25%

lower death risk

Median overall survival was 14.9 months with ivonescimab and chemotherapy, versus 12.1 months with durvalumab and chemotherapy in the late-stage trial conducted in China.